ERBB2 and gastric cancer: The phase II C013 trial demonstrated efficacy of RC48 plus toripalimab in pretreated HER2-low gastric/gastroesophageal junction cancer (GC/GEJC) patients (IHC2+/ISH- or IHC1+), reporting an objective response rate (ORR) of 46%, median progression-free survival (PFS) of 5.1 months, and median overall survival (OS) of 14.0 months (Wang et al., 2024).